Table 1.
GATA3, TRPS1, and MGP expression in breast carcinomas
| Subtype | Negative (n/%) | Positive (n/%) | Total (n) | |||
|---|---|---|---|---|---|---|
| Mild | Moderate | High | ||||
| GATA3 | ER/PR+ | 37 (6.6) | 26 (4.6) | 73 (12.9) | 429 (75.9) | 565 |
| HER2+ | 81 (23.0) | 33 (9.4) | 64 (18.2) | 174 (49.4) | 352 | |
| TNBC-NSTs | 87 (60.4) | 7 (4.9) | 8 (5.6) | 42 (29.2) | 144 | |
| TNBC-MBCs | 74 (52.9) | 30 (21.4) | 21 (6.7) | 15 (10.7) | 140 | |
| Total | 279 (23.2) | 96 (8.0) | 166 (13.8) | 660 (55.0) | 1201 | |
| MGP | ER/PR+ | 59 (10.4) | 153 (27.1) | 163 (28.8) | 190 (33.6) | 565 |
| HER2+ | 31 (8.8) | 78 (22.2) | 103 (29.3) | 140 (39.8) | 352 | |
| TNBC-NSTs | 20 (13.9) | 30 (20.8) | 44 (30.6) | 50 (34.7) | 144 | |
| TNBC-MBCs | 16 (11.4) | 25 (17.9) | 49 (35.0) | 50 (35.7) | 140 | |
| Total | 126 (10.5) | 286 (23.8) | 359 (29.9) | 430 (35.8) | 1201 | |
| TRPS1 | ER/PR+ | 39 (6.9) | 72 (12.7) | 141 (25.0) | 313 (55.4) | 565 |
| HER2+ | 28 (8.0) | 55 (15.6) | 92 (26.1) | 177 (50.3) | 352 | |
| TNBC-NSTs | 22 (15.3) | 22 (15.3) | 36 (25.0) | 64 (44.4) | 144 | |
| TNBC-MBCs | 3 (2.1) | 8 (5.7) | 17 (12.1) | 112 (80.0) | 140 | |
| Total | 92 (7.7) | 157 (13.1) | 286 (23.8) | 666 (55.4) | 1201 | |
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2; TNBC, triple-negative breast cancer; NST, no special type; MBC, metaplastic breast carcinoma